Pure Lithium Announces New York Series B Roadshow
Pure Lithium Corporation, a disruptive Boston-based vertically-integrated lithium metal battery technology company, is pleased to announce that it will conduct a roadshow in New York the week of November 18, 2024 to promote its $75M to $100M Q1 2025 Series B fundraise. The funds will support the scale-up of the Company’s technology towards commercial lithium metal battery production and a potential Initial Public Offering of the company.
Lithium metal is the "holy grail" of energy storage, a step change beyond today's lithium-ion battery. It does not require graphite, nickel, cobalt and manganese, eliminating dependence on China and enabling local battery hubs in favorable jurisdictions for the first time ever.
Since opening its Boston lab in January of 2021, Pure Lithium has made impressive strides towards commercializing the lithium metal battery. This year, the Company raised $20M in its Series A.5 with Oxy Low Carbon Ventures as the lead investor. Major progress has been made on a number of fronts towards commercial battery production. This includes:
- Robust intellectual property protection, covering all aspects of lithium metal extraction and battery production with nearly 100 patents and patent applications to date.
- Selection and patenting of the optimal cathode material (vanadium oxides and vanadyl phosphates) to pair with the lithium metal anode. This includes a joint patent application with Nobel Laureate Professor Sir Stanley Whittingham, who won the 2019 prize for Chemistry for inventing the lithium-ion battery.
- World’s best cycling data for a lithium metal battery, with plus 1,300 cycles at commercially relevant charge rates of 1C and 1D, ready for commercial scale-up.
- Signing an agreement, to be announced shortly, with a multinational company to scale-up the manufacture of Pure Lithium’s patented solid-state lithium-selective membrane, a key innovation to enabling our unique breakthrough low-cost process for the direct electrodeposition of lithium metal anodes directly from lithium-bearing brines.
- Locking-up of the first upstream supplies of lithium (the first of many eventual deals around the world) through signing of a joint development agreement with Calgary-based junior mining company E3 Lithium Inc., which will secure enough lithium for 80 million electric vehicles and investigate the economic feasibility of manufacturing lithium metal batteries in Alberta using lithium from E3’s oil field brines.
- Acquisition of all intellectual and physical assets from Buffalo-based private company Dimien Inc., a leader in vanadium pentoxide-based cathodes.
It is our conviction that Pure Lithium will be the first, and perhaps only, company to commercialize next-generation lithium metal battery energy storage, delivering lower-cost, safer, longer duration and greener batteries to displace 40-year-old lithium-ion technology. Moreover, this will be done using North American-sourced lithium and vanadium, North American production facilities and will eliminate dependence on China completely.
Should you wish on this roadshow to meet Pure Lithium Founder, Chairman and CEO Emilie Bodoin; Co-Founder, Director, Chief Scientific Officer and MIT Emeritus Professor Donald R. Sadoway; and Company Director, former Assistant Attorney General of the United States and former Governor of Massachusetts Bill Weld; along with other key members of our management team, please reach out to Emily Merkel at emerkel@purelithium.io to secure a meeting opportunity.
To learn more about how Pure Lithium is revolutionizing battery production, go to: https://www.purelithium.io/
View source version on businesswire.com: https://www.businesswire.com/news/home/20241106214153/en/
Contacts
Ross Larsen, Head of Editorial, 33 Communications
purelithium@thirtythreecomms.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Nemluvio ® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press Release
Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024.12 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213562840/en/ Atopic dermatitis affects more than 230 million people worldwide, impacting approximately 7% of people in the U.S.2-4 Often reported as one of patients’ most problematic symptoms, 87% of people with atopic dermatitis say they are seeking freedom from itch, with speed of itch relief therefore also prioritized by both patient
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press Release
Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unlike other issues facing financial services companies, fraud operates b
Capcom Announces Onimusha Way of the Sword , Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press Release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press Release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press Release
Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024.14 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212936857/en/ Atopic dermatitis is a common, chronic, and flaring infl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom